Epistaxis associated with elevation of INR in a patient switched to generic warfarin - A comment

Pharmacotherapy

Volumn 20, Issue 7 I, 2000, Pages 863-865

  Murphy, John E ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; SILDENAFIL; WARFARIN;

ANTICOAGULANT THERAPY; BIOEQUIVALENCE; DRUG EFFICACY; DRUG SAFETY; EPISTAXIS; FOOD AND DRUG ADMINISTRATION; HUMAN; INTERNATIONAL STANDARD UNIT; SHORT SURVEY;

EID: 0343953565     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.9.863.35191     Document Type: Short Survey

References (6)

1. Wagner JL, Dent LA. Epistaxis associated with elevation of INR in a patient switched to generic warfarin. Pharmacotherapy 2000;20(2):240-3.
2. Murphy JE. Generic substitution and optimal patient care. Arch Int Med. 1999;159:429-33.
3. Handler J, Nguyen TT, Rush S, Pham NT. A blinded, randomized, crossover study comparing the efficacy and safety of generic warfarin sodium to Coumadin. Preven Cardiol 1998;4:13-20.
4. Swenson CN, Grodzana F. Observational cohort study of switching warfarin sodium products in a managed care organization Am J Health-Syst Pharm 2000;57:452-5.
5. Neutel JM, Smith DHG. A randomized crossover study to compare the efficacy and tolerability of Barr warfarin sodium to the currently available Coumadin. Cardiovasc Rev Rep 1998;19:49-89.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.